SavedAdd your journal

Journals / Trends in pediatrics / 2022 / Cilt: 3 - Sayı: 2

The Evaluation of Local and Systemic Reactions to Subcutaneous House Dust Mite Allergen Immunotherapy

Şükrü Çekiç
Yakup Canıtez
Nihat Sapan
Zuhal Karali
Yağmur Hazal Şadırvan
Pages
43–46
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Although subcutaneous mite immunotherapy is a safe treatment, it should only be applied in centers with appropriate emergency equipment and trained healthcare professionals due to possible systemic reactions

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Allergen-specific immunotherapy is an effective treatment method that enables the development of immunotolerance against allergens in allergic rhinitis, asthma, and venom allergy.
📊
Key Findings & Data:Methods: Injection-related local and systemic reactions of 45 patients who received subcutaneous mite immunotherapy were evaluated retrospectively.
💡
Conclusion & Impact:Conclusion: Although subcutaneous mite immunotherapy is a safe treatment, it should only be applied in centers with appropriate emergency equipment and trained healthcare professionals due to possible systemic reactions
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Allergen-specific immunotherapy is an effective treatment method that enables the development of immunotolerance against allergens in allergic rhinitis, asthma, and venom allergy. This study investigated the local and systemic reactions during subcutaneous house dust mite allergen immunotherapy. Methods: Injection-related local and systemic reactions of 45 patients who received subcutaneous mite immunotherapy were evaluated retrospectively. Results: Forty-five children, 15 (33.3%) females and 30 (66.4%) male were included in the study. A total of 582 injections were administered. A local reaction was observed in 23 (3.94%) of all injections and the systemic reaction was observed in only 1 (0.17%) injection. Sixteen (37.7%) of the children had local reactions during the immunotherapy process and 1 (2.2%) had a systemic reaction. Conclusion: Although subcutaneous mite immunotherapy is a safe treatment, it should only be applied in centers with appropriate emergency equipment and trained healthcare professionals due to possible systemic reactions

🔖

Cite This Article

Çekiç, Ş., Canıtez, Y., Sapan, N., Karali, Z., Şadırvan, Y. H. (2022). The Evaluation of Local and Systemic Reactions to Subcutaneous House Dust Mite Allergen Immunotherapy. Trends in pediatrics, Cilt: 3 - Sayı: 2, 43–46. https://ajindex.com/articles/598881

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Cekic S, Sapan N. Allergen specific immunotherapy. J Curr Pediatr. 2015;13:46-55
  2. Coop CA, Tankersley MS. Patient perceptions regarding local reactions from allergen immunot herapy injections. Ann Allergy Asthma Immunol. 2008;101:96-100
  3. Yang L, Zhu R.Immuno therapy of house dust mite allergy. HumVaccin Immunother. 2017;13:2390-6
  4. Coulet M, Van Borssum Waalkes M, Cox P, Lohuis J. In vitro and in vivo pharmacodynamic properties of the fluoroquinolone ibafloxacin. J Vet Pharmacol Ther. 2002;25:401-11
  5. Chen J, Zhao Y, Li B, et al. A multicenter study of the clinical features of allergic rhinitis in central China. Am J Rhinol Allergy. 2014;28:392-6
  6. Platts-Mills T, de Weck AL, Aalberse R, et al. Dust mite allergens and asthma: a worldwide problem. J Allergy Clin Immunol. 1989;83:416-27
  7. Ulrik CS, Backer V. Markers of impaired growth of pulmonary function in children and adolescents. Am J Respir Crit Care Med. 1999;160:40-4
  8. Sheikh A, Hurwitz B, Nurmatov U, van Schayck CP. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev. 2010;2010:CD001563
  9. Eifan AO, Calderon MA, Durham SR. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther. 2013;13:1543-56
  10. Calderon MA, Casale TB, Nelson HS, Demoly P. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. J Allergy Clin Immunol. 2013;132:1322-36 11. Erekosima N, Suarez-Cuervo C, Ramanathan M, et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review. Laryngoscope. 2014;124:616-27
  11. Cox L,Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The world allergy organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol. 2010;125:569- 74
  12. Agache I, Lau S, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: House dust mite-driven allergic asthma. Allergy. 2019;74:855-73
  13. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102:558-62
  14. Tankersley MS, Butler KK, Butler WK, Goetz DW. Local reactions during allergen immunotherapy do not require dose adjustment. J Allergy Clin Immunol. 2000;106:840-3
  15. Schubert R, Eickmeier O, Garn H, et al. Safety and immunogenicity of